HK Stock Market Move | CK ASSET (01113) rose over 4% as the mid-term results disclosure approaches. UBS expects a special dividend in the first half of the year.
Cheung Kong Property Holdings Limited (01113) has risen over 4%, as of the time of publication, up 3.66%, priced at HKD 48.12, with a transaction amount of HKD 168 million.
CK ASSET (01113) rose over 4%, and as of the time of writing, it is up 3.66%, trading at HKD 48.12, with a trading volume of HKD 168 million.
In terms of news, CK ASSET held a board meeting today to approve the publication of the company's mid-term results for 2026 and to consider the distribution of a mid-term dividend. UBS previously pointed out that, to reflect the substantial proceeds from the sale of UKPN (HKD 8.4 billion), Longfor is expected to announce a special dividend of HKD 0.39-0.82 per share for the first half of 2026, which implies a payout ratio of 16%-34%. Considering the banks forecast of an organic dividend of HKD 1.78 per share for the fiscal year 2026, the total dividend yield is expected to reach 5%-6%.
Related Articles
HK Stock Market Move | TH MEDICAL-B (02697) rose over 8%, with a total market value exceeding HKD 30 billion. The room temperature mechanical infusion business is expected to experience strong growth.

HK Stock Market Move | IMAGI INT'L (00585) surged nearly 12% during trading as Tan Wenkang joined the company's board, bringing experience in cutting-edge technology and capital operations.

Chongqing Pharscin Pharmaceutical (002907.SZ): ORIC-1327 Phosphate Eye Drops Obtained Approval for Clinical Drug Trials
HK Stock Market Move | TH MEDICAL-B (02697) rose over 8%, with a total market value exceeding HKD 30 billion. The room temperature mechanical infusion business is expected to experience strong growth.
HK Stock Market Move | IMAGI INT'L (00585) surged nearly 12% during trading as Tan Wenkang joined the company's board, bringing experience in cutting-edge technology and capital operations.

Chongqing Pharscin Pharmaceutical (002907.SZ): ORIC-1327 Phosphate Eye Drops Obtained Approval for Clinical Drug Trials

RECOMMEND





